Fusion Pharmaceuticals Inc. Stock: price and management transactions · United States · SEC (Form 4)

About Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. is a biopharmaceutical company focused on precision oncology, with a particular specialization in next-generation radiopharmaceuticals and, more specifically, targeted alpha radioconjugates. The company was founded in December 2014 under the Canada Business Corporations Act, but it developed as a cross-border organization with operations in Hamilton, Ontario and Boston, Massachusetts. Its SEC filings show a headquarters in Hamilton and a U.S. office in Boston, which is relevant for investors following the company in the broader NYSE/NASDAQ-listed U.S. biotech universe, even though its corporate roots were Canadian. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1805890/000095017024034172/fusn-20231231.htm?utm_source=openai)) Fusion’s core investment case was built on a highly specialized oncology platform: delivering alpha-emitting radioactive payloads directly to tumor cells to maximize anti-cancer effect while limiting systemic exposure. The company’s clinical portfolio included FPI-2265, a PSMA-targeted program for metastatic castration-resistant prostate cancer, FPI-1434 targeting IGF-1R, and FPI-2068, a bispecific EGFR/cMET radioconjugate. This placed Fusion in a niche but scientifically demanding segment at the intersection of oncology, nuclear medicine, and targeted therapeutics. ([careers.astrazeneca.com](https://careers.astrazeneca.com/job/waltham/scientist-theranostics-and-radiation-science/7684/95024927536?utm_source=openai)) From a competitive standpoint, Fusion differentiated itself through radiopharmaceutical expertise rather than scale. The company pursued a platform strategy centered on personalized radiation therapy and high-unmet-need oncology indications, which helped it stand out from broader oncology developers. Early financing came from a mix of strategic and specialist healthcare investors, including Johnson & Johnson Innovation, Varian, OrbiMed, and other venture healthcare backers. That support reflects the market’s interest in alpha-therapy assets as a potentially important modality in difficult-to-treat cancers. ([fusionpharma.com](https://fusionpharma.com/fusion-pharmaceuticals-launches-with-a-25m-usd-series-a-financing-to-develop-targeted-radiotherapeutics-as-cancer-treatments/?utm_source=openai)) The most important recent corporate development was AstraZeneca’s acquisition of Fusion. The transaction was announced in March 2024 and completed on June 4, 2024. As a result, Fusion is no longer an independent listed biotech in the way investors would typically model a standalone small-cap oncology company. Instead, its technology and programs have been folded into AstraZeneca, a major global pharmaceutical group, as part of the latter’s oncology strategy. AstraZeneca said the acquisition supports its ambition to replace traditional chemotherapy and radiotherapy regimens with more targeted treatments. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1805890/000119312524070702/d739068ddefa14a.htm?utm_source=openai)) For French-speaking investors, Fusion should therefore be viewed primarily as a former U.S.-market biotech asset with a strong scientific moat in radioconjugates, now strategically embedded within AstraZeneca. Its significance lies less in standalone financial metrics and more in the quality of its platform, the clinical optionality of its pipeline, and the strategic value of its oncology assets within a large-cap pharmaceutical framework.